Emergent BioSolutions, a specialty pharmaceutical company and contract manufacturer, has been awarded a contract worth approximately $25 million by the US Department of State to supply Trobigard (atropine sulfate [2 mg]/obidoxime chloride [220 mg]) auto-injector, a drug and device combination product for emergency use in the event of nerve agent or organophosphate poisoning.

The contract consists of a 12-month base period of performance with a six-month option period to manufacture and deliver the Trobigard product and training for auto-injectors as well as to support the government’s emerging requirements for other existing or custom-made auto-injectors. 

The drug is designed for intramuscular self- or buddy-administration of atropine sulfate and obidoxime chloride for pre-hospital intervention. 

Trobigard has not been approved by the US Food and Drug Administration or any other regulatory agency.

Source: Emergent BioSolutions